Archived Facts

Shares of Tranzyme Inc. slumped to new lows Friday, a day after the company said its diabetic gastroparesis drug TZP-102 failed in a clinical trial.

Popular Posts:

Incoming search terms:

Related Posts:

Leave a Reply